|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Currently, along with traditional disease modifying anti-rheumatic drugs (DMARDs), TNF-α, IL-12/23 and IL-17 are available for treatment of such diseases as ankylosing spondylitis (AS) and psoriatic arthritis (PsA).
|
29283375 |
2017 |
|
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
No differences were found in IMT values at the level of internal carotid between the 2 populations.The significantly lower carotid atherosclerosis found in patients with AS treated with TNF antagonists than in healthy controls shows the important complementary role of this treatment in reducing vascular disease progression probably by decreasing inflammation.
|
29979389 |
2018 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
TNF-α inhibitors may be a promising treatment for AS, but carries an increased incidence rate of adverse events and injection-site reaction.
|
28640088 |
2017 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
TNF-α antagonist indications were ankylosing spondylitis (n = 8), inflammatory bovel diseases (n = 7) and rheumatoid arthritis (n = 4).
|
29028148 |
2018 |
|
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A great deal of evidence has shown that non-human leucocyte antigen (HLA)-B27 genes may play crucial roles in the aetiology of ankylosing spondylitis (AS), but there is little evidence of a relationship with tumour necrosis factor (TNF)alpha gene variation.
|
17472990 |
2007 |
|
Ankylosing spondylitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To review the literature about the effect of TNF α inhibitor on radiographic progression and disease activity in patient with AS.
|
30220240 |
2019 |
|
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Runt-related transcription factor 3 (RUNX3), tumor necrosis factor family member-associated NF-κB activator binding kinase 1 binding protein (TBKBP1), and peroxisome proliferator-activated receptor-gamma coactivator 1 beta (PPARGC1B) have recently been found to be associated with susceptibility to AS in patients of Western European descent.
|
25494292 |
2015 |
|
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lack of association of TNF-alpha promoter polymorphisms with ankylosing spondylitis: a meta-analysis.
|
19720680 |
2009 |
|
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A total of 54 patients with RA, 10 with PsA and 22 with AS were genotyped by polymerase chain reaction for the -308 TNFalpha promoter polymorphism.
|
16720636 |
2007 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor (TNF) blockers have a high efficacy in treating Ankylosing Spondylitis (AS), yet up to 40% of AS patients show poor or even no response to this treatment.
|
31195969 |
2019 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Certolizumab-pegol is the first and only pegylated TNF-α antagonist approved in the treatment of Crohn's disease, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
|
30225952 |
2018 |
|
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This protective effect of variant promoter alleles could be related to differences in TNFalpha production or could reflect the association of different B27 haplotypes with ankylosing spondylitis.
|
9704649 |
1998 |
|
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
A novel gene variation of TNFalpha associated with ankylosing spondylitis: a reconfirmed study.
|
17472990 |
2007 |
|
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Secukinumab, an interleukin-17A (IL-17A) antagonist, is the first non-TNF alpha inhibitor agent licensed for ankylosing spondylitis (AS), which opens up a new era of alternative cytokine targets beyond TNF.
|
30576610 |
2019 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Pe-TNF transgenic mouse model provides a unique opportunity to explore potential mechanisms whereby TNF-alpha may initiate an autoimmune arthritis resembling ankylosing spondylitis.
|
9568723 |
1998 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate temporal changes in structural progression assessed by serial conventional radiography and magnetic resonance imaging (MRI) of the sacroiliac joints (SIJs) and spine in patients with ankylosing spondylitis (AS) treated with tumour necrosis factor (TNF) inhibitor for 5 years.
|
30422733 |
2019 |
|
Ankylosing spondylitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Consequently, the findings of this experiment demonstrated that AS in mice that were given <i>Chrysanthemum indicum</i> extract had lower level of TNF-<i>α</i>, IL-1<i>β</i>, and IL-6 (<i>P</i> < 0.05) and increased level of catalase (CAT), glutathione peroxidase (GSH-PX), and superoxide dismutase (SOD) (<i>P</i> < 0.05).
|
28261616 |
2017 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumour necrosis factor (TNF)-α inhibitors are highly used in Romania for the treatment of autoimmune disorders, such as rheumatoid arthritis (RA), psoriasis, inflammatory bowel diseases, and ankylosing spondylitis.
|
29792084 |
2018 |
|
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We report the clinical cases of two patients affected by a CNS demyelinating disease and ankylosing spondylitis who were successfully treated with secukinumab, providing additional evidence of the feasibility of this therapeutic option when the use of TNF inhibitors is discouraged by challenging comorbidities.
|
31398658 |
2019 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Stimulation of PBMCs by exogenous leptin significantly increased the production of IL-6 and TNF-alpha in PBMCs from patients with AS in a dose-dependent fashion and these increases were much exacerbated compared to controls.
|
19059800 |
2009 |
|
Ankylosing spondylitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
RESULTS The results suggest that AS mice has higher levels of TNF-α, IL-1β, and IL-6 (p<0.01 for all), and lower levels of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-PX) (p<0.01 for all).
|
29849019 |
2018 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The TNF inhibitor golimumab (GLM) is a treatment option in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS).
|
30415451 |
2019 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effect of Systemically Used Anti-Tumor Necrosis Factor-α Medication on the Corneal Epithelium and Stroma of Patients with Ankylosing Spondylitis.
|
26731089 |
2017 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with AS had higher serum TNF-α and leptin concentrations than controls (52.3 vs. 1.5 pg/mL and 17.2 vs. 9.0 µg/mL, respectively).
|
28534699 |
2017 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Golimumab (GOL), a tumor necrosis factor-α inhibitor (TNFi), has proven to be effective in the treatment of AS.
|
30385705 |
2019 |